In the first 3 months of 2010, the US FDA is expected to make a decision on marketing applications for several drugs that could advance treatment in their respective indications. Two of these drugs - a once-weekly glucagon-like peptide 1 (GLP1) agonist and an inhalable formulation of insulin- have potential safety concerns that could affect their approvability. Another, already approved drug may have its label expanded to treat hepatic encephalopathy, an area of unmet medical need.
展开▼
